Associations between purine metabolites and clinical symptoms in schizophrenia by Yao, JK et al.
Associations between Purine Metabolites and Clinical
Symptoms in Schizophrenia
Jeffrey K. Yao1,2,3*, Ruth Condray1,2, George G. Dougherty Jr.1,2, Matcheri S. Keshavan2,4,
Debra M. Montrose2, Wayne R. Matson5, Joseph McEvoy6, Rima Kaddurah-Daouk6, Ravinder D. Reddy1,2
1 Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States of America, 2Department of Psychiatry, Western Psychiatric Institute & Clinic,
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America, 3Department of Pharmaceutical Sciences, University of Pittsburgh School of
Pharmacy, Pittsburgh, Pennsylvania, United States of America, 4 Beth Israel Deaconess Medical Center and Harvard University, Boston, Massachusetts, United States of
America, 5 Bedford Veterans Affairs Medical Center, Bedford, Massachusetts, United States of America, 6Duke University Medical Center, Durham, North Carolina, United
States of America
Abstract
Background: The antioxidant defense system, which is known to be dysregulated in schizophrenia, is closely linked to the
dynamics of purine pathway. Thus, alterations in the homeostatic balance in the purine pathway may be involved in the
pathophysiology of schizophrenia.
Methodology/Principal Findings: Breakdown products in purine pathway were measured using high-pressure liquid
chromatography coupled with a coulometric multi-electrode array system for 25 first-episode neuroleptic-naı¨ve patients
with schizophrenia at baseline and at 4-weeks following initiation of treatment with antipsychotic medication. Associations
between these metabolites and clinical and neurological symptoms were examined at both time points. The ratio of uric
acid and guanine measured at baseline predicted clinical improvement following four weeks of treatment with
antipsychotic medication. Baseline levels of purine metabolites also predicted clinical and neurological symtpoms recorded
at baseline; level of guanosine was associated with degree of clinical thought disturbance, and the ratio of xanthosine to
guanosine at baseline predicted degree of impairment in the repetition and sequencing of actions.
Conclusions/Significance: Findings suggest an association between optimal levels of purine byproducts and dynamics in
clinical symptoms and adjustment, as well as in the integrity of sensory and motor processing. Taken together, alterations in
purine catabolism may have clinical relevance in schizophrenia pathology.
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Introduction
There is abundant evidence for impaired antioxidant defense
system (AODS) and presence of oxidative stress in patients with
schizophrenia (SZ) [1–6], suggesting that free radical-mediated
pathology may have a role in the pathophysiology of SZ.
Free radicals are reactive chemical species generated during
normal metabolic processes involving oxygen and nitric oxide,
which in excess can lead to membrane damage. Under physio-
logical conditions the potential for free radical-mediated damage is
kept in check by the AODS, comprising a series of enzymatic and
non-enzymatic components. These enzymes act cooperatively at
different sites in the free radical pathways. We have previously
observed that a dynamic state is kept in check during the redox
coupling under normal conditions [7–8]. By contrast, lack of such
correlations in brains of SZ patients point to a disturbance of
redox coupling mechanisms in the AODS, possibly resulting from
a decreased level of glutathione (GSH) as well as age-related
decreases of oxidized GSH and glutathione reductase activities.
In addition to GSH redox coupling mechanism, purine
catabolism may be an underappreciated component of the
homeostatic response of mitochondria to oxidant stress and may
play a critical role in slowing progressive mitochondrial dysfunc-
tion in certain disease states [9]. In response to oxidative stress,
decreased energy charge or nucleic acid damage, purine
metabolism shifts to favor breakdown to xanthine and uric acid.
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Recently, we [8] have further shown that a shift favorable to
Xanthosine production from Xanthine, resulting in decreased uric
acid (UA) levels in the first-episode neuroleptic-naı¨ve patients with
schizophrenia (FENNS). Specifically, the reduced UA/guanosine
ratio was nearly normalized after 4-week of antipsychotic
treatment. In addition, there are tightly correlated precursor and
product relationships within purine pathways; although some of
these correlations persist across disease or medication status, others
appear to be lost among FENNS. Taken together, these results
suggest that the potential for steady formation of antioxidant UA
from purine catabolism is altered early in the course of illness.
In this study, we extend our previous findings [8] to test whether
homeostatic imbalance in purine catabolism is associated with
specific clinical characteristics observed in FENNS at baseline
and/or 4 weeks after antipsychotic treatment.
Materials and Methods
First-Episode Neuroleptic-Naı¨ve (FENN) Patients
Twenty five patients were recruited (Table 1) in their first
episode of psychosis after they provisionally met DSM-IV criteria
for schizophrenia, schizophreniform or schizoaffective disorder
based on Structured Clinical Interview for DSM Disorders
(SCID). The initial diagnostic assessments were performed at
consensus diagnostic conferences including SCID and all clinical
data, and attended by research faculty and staff, chaired by one of
the authors (MSK or DM). All subjects signed informed consent
after a full explanation of the study. The study was approved by
both VA Pittsburgh Healthcare System and the University of
Pittsburgh Institutional Review Board.
Blood samples were obtained in patients at baseline (FENNS-
BL) prior to the initiation of antipsychotic agents. A second set of
blood samples was obtained in the same patient individuals about
4 weeks after initiation of treatment (FENNS-4w) with one or
more of the following antipsychotic drugs: risperidone (n = 17),
olanzapine (n = 5), quetiapine (n = 2), aripiprazole (n = 1) and
haloperidol (n = 2). The number adds up to more than 25 because
of polypharmacy.
Clinical symptoms were rated by experienced research
clinicians at both time points using standard rating scales. Our
primary question concerned the association between purine
catabolism and the severity of psychiatric disturbance in patients
during the early phase of their illness. Severity of clinical
presentation was evaluated using the Global Assessment Scale
(GAS), which has a high degree of sensitivity to clinical change
over time [10]. The relationships among purine metabolites and
specific clinical symptom dimensions were additionally explored
and included ratings of positive and negative symptoms (Positive
Symptoms scale from the Brief Psychiatric Rating Scale (BPRS)
[11]; Scale for Assessment of Negative Symptoms (SANS) [12])
and neurological symptoms (Neurological Evaluation Scale (NES)
[13]). As expected, patients showed improvement in clinical
symptoms and clinical functioning after 4 weeks of treatment with
antipsychotic drugs (Table 2).
Sample Preparation
All blood samples were collected in the morning after overnight
fasting. Samples were prepared for analysis by extraction in
acidified acetonitrile and analyzed by liquid chromatography with
electrode Coul Array (LCECA) system as previously described
[8,14–15]. Briefly, freshly drawn blood with anticoagulant citrate
dextrose (ACD) was centrifuged at 7506g for 7 minutes to remove
RBC and stored at 280uC freezer. 250 ml aliquot of stored sample
was mixed with 1 ml of acetonitrile/0.4% acetic acid at 225uC
and vortexed for 45–60 sec, then temperature was brought to
215uC in a cold block, and vortexed again for 30–45 sec. Samples
were centrifuged for 15 min at 12,0006g at 4uC. In total, 1 ml of
the resulting supernate was transferred to a 2 ml screw top vial and
evaporated under vacuum. It is critical that the vacuum is
sufficient to freeze the sample during this step. The sample was
reconstituted in 200 ml of mobile phase A and 100 ml were loaded
onto two autosampler vials, one of which was archived at 280uC.
Profiles are stable in acetonitrile extract, dried extract and mobile
phase diluted extract.
During the sample preparation, pools were created from equal
volumes of aliquots of all samples. All assays were run in sequences
that include 10 samples, authentic reference standard mixtures of
80 known compounds, pools of all samples and duplicate
preparations of the same sample. Duplicates are spaced at short
and long intervals through the run to reflect the performance of
the total data base. Run orders of all samples in this study were
randomized. The sequences minimized possible analytical artifacts
during further data processing. Pools and duplicates were used to
access the precision of the entire data set. In addition, the pools
were used as references for time normalization (stretching). A
practical advantage of LCECA for this study is the relative
freedom from maintenance events. This is important for the
generation of consistent databases from large numbers of samples
over extended time periods. In our earlier work we have run
LCECA continuously for 24 h per day over 6 months.
High-Pressure Liquid Chromatography Coupled With
Electrochemical Coulometric Array (LCECA) Detection
The LCECA method used in this work has been described
earlier [8,14–16]. Briefly the liquid chromatographic method
employs an A mobile phase (10.3 g l21 sodium pentane sulfonate,
5 ml l21 glacial acetic acid) and a B mobile phase (methanol/
acetonitrile/isopropanol 8/1/1, 8 g l21 lithium acetate, 20 ml l21
glacial acetic acid). A gradient is run from 100% A to 100% B over
120 min. The electrochemical array of 16 series coulometric
detectors is set from 0 to 900 mv in equal 60 mv increments from
detector 1–16. In this mode a compound passing through a
coulometric electrode is oxidized by 100% of the thermodynam-
ically possible amount. This results in a characteristic signature for
a compound expressed as a ratio on sequential electrodes. This
ratio provides a high degree of qualitative certainty, which can be
set for any particular study [17]. The gradient and detector
conditions typically provide responses at the 500 pg ml21 level
(5 pg on column) for ca 1500–2000 compounds in biological
samples. In comparison with Mass Spectrometry (MS) a specific
thermodynamically determined response ratio and retention time
in an LCECA method does not carry as much qualitative certainty
as an accurate mass peak or fragmentation pattern in MS/MS.
Table 1. Subject characteristics of first-episode neuroleptic-
naı¨ve patients with schizophrenia.
Demographical features Male Female
Number 19 6
Age (yrs, mean 6 SD) 21.465.5 26.3610.6
Educations (yrs) 11.862.9 12.364.6
Weight (lbs) 156.1643.5 120.0619.2
Height (inches) 68.264.1 64.361.7
Body mass index (BMI) 23.964.8 20.763.0
doi:10.1371/journal.pone.0042165.t001
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However, in comparison with MS for the classes of compounds
measurable on LCECA the sensitivity of ca 500 pg ml21 is
typically one to two orders of magnitude lower than can be
achieved with MS. As an example we conducted a study directed
at identifying metabolites implied by the presence of multiple
responses in an LCECA method following Huntington’s disease
patients treated with phenyl butyrate [18]. The LCECA method
employed 40 ml of plasma. It was necessary to concentrate and
fractionate 4 ml of plasma to obtain sufficient material for
qualitative identification in a parallel LCECA/LCMS system.
The LCECA method with 100% efficient electron transfer also has
an inherent quantitative control based on integration of the total
coulombs of the peaks [18] and calculation of quantity by
Faraday’s law. Thus, it is independent of such factors as variations
in ionization efficiency as a result, for instance, of column bleed.
Inter-laboratory/inter-method comparisons are a field in and of
themselves. Well designed studies are highly expensive and have to
take into account standards, preparative methods, sample splitting
techniques and so on, as well as the instrumentation and
parameters of instrument usage. Initial efforts are frequently
discouraging. As an example the initial round of the multi center/
method ESCOT study for 8 hydroxy 2’deoxyguanosine measure-
ments initially returned values differing by a factor of 1000 with
the higher values resulting from source artifacts in a gas
chromatography-mass spectrometry (GC-MS) method.
Enzyme-linked immunosorbent assay techniques for this same
analyte in urine are typically comparable to electrochemical
methods for controls and standards but a factor of 2–5 higher in
various disorders, whereas GC-MS techniques for this analyte in
CSF have been reported as 10,000 times higher compared with
electrochemical techniques.
Statistical Analyses
The relationship between the purine analytes and clinical
symptom ratings was examined for both time points. Descriptive
statistics are provided in Yao et al. [8,15] for the purine
metabolites and tests of differences for these analytes between
baseline and 4 weeks for patients, as well as comparisons between
the analyte levels of age-matched healthy volunteers and patients
at each time point. The focus of the present report concerns the
relationships between ratings of clinical symptoms for this sample
of FENNS patients and plasma levels of those metabolites that
previously showed altered interactions within the purine pathway
[8]: (1) single metabolites, including guanine, guanosine, xantho-
sine, xanthine, uric acid; (2) ratios of product to precursor,
including guanine/guanosine, xanthine/guanine, uric acid/gua-
nosine, uric acid/guanine, uric acid/xanthosine, xanthosine/
guanosine, xanthosine/guanine.
Tests of the hypothesis that correlation coefficients involving the
selected purine analytes and clinical symptoms were equal to zero
were computed separately for the data recorded at baseline and
the data measured at four weeks. Normality of data was estimated
with Shapiro-Wilk Test of Normality (p.0.05); variables deter-
mined to approximate, or able to be transformed (ln, natural log)
to approximate, normality were evaluated using parametric tests
(paired-samples t-test; Pearson r correlation coefficient). Non-
parametric tests (related-samples Wilcoxon Signed Rank Test;
Kendall t rank correlation coefficient) were used for those
measures determined not normally distributed. Bonferroni cor-
rection was applied to control Type I error potentially associated
with the multiple tests of our primary question, which involved 12
measures of purine catabolism at the two time points and
improvement in patients’ psychiatric disturbance (GAS, Global
Assessment Scale) after one month of neuroleptic treatment:
adjusted a for 24 comparisons: 0.05/24 = 0.0021; trend signifi-
cance: 0.10/24 = 0.0042. Tests of the hypothesis that correlations
at baseline and at 4 weeks were equal were additionally computed
to screen for any baseline-to-four week between group (unmed-
icated versus medicated) correlation differences. This test for the
difference between dependent correlations was computed using
the procedure described by Bruning and Kintz [19].
Results
The ratio of uric acid/guanine measured at baseline predicted
improvement in clinical adjustment (GAS score at 4 weeks minus
GAS score at baseline) after four weeks of treatment with
neuroleptic drug. Following normalization of the data by natural
log, this association was statistically significant (Pearson
r =20.643, p = 0.001), and involved an inverse relationship
indicating that a lower initial proportion of product (uric acid) to
precursor (guanine) was associated with greater improvement in
clinical adjustment one month later (Figure 1A). In contrast, the
association between the ratio of uric acid to guanine ratio
measured at four weeks and clinical improvement (GAS scores)
four weeks following initiation of neuroleptic treatment was not
significant (Pearson r =20.215, p = 0.30) (Figure 1B). The
difference between these two correlations was statistically signif-
icant (t =22.32, df = 22, p,0.05).
Correlation coefficients for the relationships obtained between
the selected purine analytes and clinical symptoms are presented in
Table 3 for the data recorded at baseline and in Table 4 for the
data collected at four weeks.
Findings from our exploration of associations among purine
metabolites and specific symptom dimensions are additionally
suggestive about domains of behavior that may be influenced by
an imbalance in purine catabolism. Because of the exploratory
nature of these latter analyses, p-levels were not corrected. Results
Table 2. Clinical assessments of first-episode neuroleptic-naı¨ve patients with schizophrenia (n = 25).
Rating scales Baseline 4-wk follow-up p
Brief Psychiatric Rating Scale (total)* 52.5868.90 42.9267.50 ,0.001{
Brief Psychiatric Rating Scale–Positive Symptoms 15.7263.25 11.8064.29 0.001{
Scale for Assessment of Negative Symptoms 45.08610.30 43.0069.09 0.410{
Global Assessment Scale 30.4069.10 37.76611.79 0.001{
*missing data for 1 patient.
{Paired samples t-test.
{Related-samples Wilcoxon Signed Rank Test.
doi:10.1371/journal.pone.0042165.t002
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showed that the ratio of xanthosine to guanosine at baseline was
positively correlated with the neurological symptom involving the
sequencing of complex motor actions (Figure 2A). This ratio
(xanthosine:guanosine) was also correlated with a factor that
represents a composite of repetitive motor responses [20]
(Figure 2B). Relationships were additionally observed between
baseline guanosine levels and thought disturbance (Figure 3A), and
between baseline uric acid levels and sensory integration
(Figure 3B).
Discussion
Homeostatic imbalance of purine catabolism in
schizophrenia
Increasing evidence suggests that mitochondrial pathology and
oxidative stress may be one of the critical components in the
pathophysiology and treatment outcome of schizophrenia [1–8].
Purine catabolism may contribute to mitochondrial antioxidant
defense by producing the antioxidant uric acid [9]. Failure to
maintain elevated xanthine and uric acid occurred contempora-
neously with progressive mitochondrial dysfunction. On the other
hand, increased levels of uric acid may be considered as a marker
of oxidative stress [21,22] due to accumulation of reactive oxygen
species [23]. Therefore, uric acid can be served as both anti- and
prooxidant in the AODS.
In man, uric acid is the final product of purine catabolism [24],
which has been implicated as a risk factor and cause of numerous
pathological conditions. Abnormally high plasma (or serum) uric
acid has been related to cardiovascular disease, gout, hypertension,
and renal disease, whereas low levels of plasma (or serum) uric acid
have been linked to Alzheimer’s disease, multiple sclerosis, optic
neuritis, and Parkinson’s disease [6]. Previously, we have also
demonstrated that plasma levels of uric acid are reduced in
chronic [25] as well as first-episode neuroleptic-naı¨ve patients with
schizophrenia [26]. Although some studies have indicated that uric
acid may play a role in the development or progression of such
diseases, it remains unclear whether an increased uric acid
contributes to the cause or is simply a consequence of these
pathologic conditions [27].
Moreover, in healthy control subjects, there exist tight product-
precursor correlations within purine catabolism [8]. Interestingly,
some of these correlations (i.e., conversion of hypoxanthine to
xanthine) persist across disease or medication status, others (i.e.,
conversions of guanosine to xanthine, and xanthine to uric acid)
are lost among these same FENNS patients [8]. Similar findings of
lacking a control mechanism used by healthy control subjects were
also demonstrated in the tryptophan pathway from these same
patient group [15], indicating some metabolite interactions within
purine catabolism were altered in FENNS patients. Taken
collectively, purine catabolism appears to be a homeostatic
response of mitochondria to oxidative stress and may play protect
against progressive mitochondrial dysfunction in schizophrenia.
Thus, our data as well as findings from other investigators are
consistent with the notion of free radical-mediated neurotoxicity in
schizophrenia [1–6].
Purine metabolites and clinical improvement
Improvement in clinical functioning was associated with initial
levels of uric acid and guanine in this sample of first-episode
neuroleptic-naı¨ve schizophrenia patients. The direction of this
relationship indicates that a lower initial proportion of product
(uric acid) to precursor (guanine) was associated with greater
improvement in clinical functioning one month later. Thus, the
lower the level of a patient’s initial ratio of uric acid to guanine, the
greater their overall clinical improvement at one month.
The initial severity of clinical dysfunction may be important to
this relationship. As a group, the average level of clinical
functioning reflected impairment at both time points, with mean
values (,40) falling within the range typically observed for former
inpatients likely to be readmitted to hospital [10]. Descriptively,
degree of clinical improvement achieved by the patient group in
the present study represented an increase from ‘‘Unable to function in
almost all areas …’’ at baseline to ‘‘Major impairment in several areas …’’
one month later (GAS anchor points [10]). It may be appropriate,
therefore, to qualify interpretation of findings based on this degree
of severity.
Purine metabolites and neurological symptoms
Neurological abnormalities are observed in schizophrenia
patients even at the time of their first episode of psychosis and
Figure 1. Associations between clinical improvement at 4
weeks and ratio of uric acid to guanine in first-episode
neuroleptic-naı¨ve patients with schizophrenia at baseline (A)
or at 4-week (B) after antipsychotic treatment. Abbreviations:
GAS, Global Assessment Scale; ln, natural logarithm.
doi:10.1371/journal.pone.0042165.g001
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before the initiation of antipsychotic drug treatment [20,28–31].
Moreover, neurological signs are correlated with clinical symp-
toms in unmedicated patients [32]. Significant heritability, or
familial influence, has also been reported for several aspects of
neurologic-related responding [33]. This overall pattern of
findings has led some researchers to suggest that neurological
abnormalities may represent a biological marker of schizophrenia
risk. Finally and importantly, neurological signs are predictive of
neuropsychological and cognitive performance in schizophrenia
patients and healthy individuals [20,34], and related to measures
of neuroanatomical regions that are relevant for some of the
cognitive deficits associated with this mental disorder [29,31].
Findings from our present study suggest such interrelationships are
also associated with alterations in purine catabolism in schizo-
phrenia.
Purine metabolites were also linked to neurological and
cognitive symptoms in our exploratory analyses based on this
sample of FENNS patients. Firstly, motor responses recorded at
baseline were associated with initial or baseline level of the ratio of
xanthosine to guanosine. As shown in Figure 2A and 2B, the
direction of these relationships indicates that a higher initial
proportion of product (xanthosine) to precursor (guanosine) was
Table 3. Correlation coefficients between purine metabolites and clinical assessments from first-episode neuroleptic-naive
patients with schizophrenia at baseline before antipsychotic treatment.
Purine metabolites GAS BPRS-PSS SANS BPRS-TD SI MC RM SCMA
G* 0.414 20.099 0.062 20.132 20.324 0.008 20.205 20.145
Gr{ 0.151 20.300 20.014 20.323 20.298 0.035 20.234 20.203
Xant{ 0.153 0.063 20.118 0.069 20.311 20.025 0.092 0.203
Xan{ 20.014 20.080 0.027 20.038 20.187 20.025 20.048 20.123
UA* 0.033 20.191 20.121 20.207 20.402 20.107 20.317 20.238
G/Gr{ 0.224 0.136 0.108 0.127 0.102 20.008 0.110 0.114
Xan/G* 20.486 0.081 20.175 0.119 0.145 20.008 0.078 20.045
UA/Gr* 20.224 0.260 0.033 0.294 0.261 20.107 0.278 0.274
UA/G* 20.643{ 20.011 20.217 0.039 0.050 20.090 0.008 0.017
UA/Xant{ 20.170 20.157 0.081 20.181 0.102 20.025 20.206 20.309
Xant/Gr* 0.172 0.055 20.151 0.110 0.054 0.008 0.491 0.506
Xant/G{ 20.075 0.045 20.141 0.099 20.017 0.057 0.206 0.258
*Pearson correlation coefficient was calculated following transformation of the data (except MC) to natural logarithm.
{Kendall’s tau rank correlation coefficient was measured when those data determined not normally distributed.
{Significance with p=0.001 in boldface after the Bonferroni correction.
Abbreviations: G, guanine; Gr, guanosine; Xant, xanthosine; Xan, xanthine; UA, uric acid; GAS, Global Assessment Scale; BPRS, Brief Psychiatric Rating Scale; PSS,
Positive Symptoms Scale; SANS, Scale for Assessment of Negative Symptoms; TD, Thought disorder; SI, Sensory Integration; MC, Motor Coordination; RM, Repetitive
Motion; SCMA, Sequencing Complex Motor Acts.
doi:10.1371/journal.pone.0042165.t003
Table 4. Correlation coefficients between purine metabolites and clinical assessments from first-episode neuroleptic-naive
patients with schizophrenia 4 weeks after initiating antipsychotic treatment.
Purine metabolites GAS BPRS-PSS SANS BPRS-TD SI MC RM SCMA
G* 0.088 0.021 20.215 0.090 20.260 20.108 20.146 20.072
Gr* 20.067 20.004 20.178 0.086 20.163 0.012 20.088 20.141
Xant{ 0.456 20.186 20.222 0.011 20.146 0.029 20.064 20.094
Xan{ 20.085 20.111 20.051 20.166 20.393 20.264 20.198 20.127
UA* 0.061 20.028 20.065 20.015 20.343 20.108 20.070 0.006
G/Gr* 0.108 0.021 20.099 0.008 20.104 20.147 20.059 0.028
Xan/G{ 20.297 20.071 0.330 20.173 0.142 20.029 0.057 0.072
UA/Gr{ 0.163 0.081 0.108 20.068 20.096 20.029 0.090 0.072
UA/G{ 20.215 0.038 0.303 20.008 0.128 0.069 0.165 0.112
UA/Xant{ 20.312 0.143 0.070 0.015 20.117 0.147 20.002 0.028
Xant/Gr{ 0.436 20.098 0.029 20.019 0.066 0.029 0.069 0.072
Xant/G{ 0.175 20.126 0.082 20.098 0.192 20.010 0.100 0.072
*Kendall’s tau rank correlation coefficient was measured when those data determined not normally distributed.
{Pearson correlation coefficient was calculated following transformation of the data (except those data from BPRS-TD, MC, and SCMA) to natural logarithm.
Abbreviations: See footnote of Table 3.
doi:10.1371/journal.pone.0042165.t004
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associated with greater impairment in motor tasks. Thus, the higher
a patient’s initial or baseline ratio of xanthosine to guanosine, the
greater his or her motor impairment was before initiating
treatment with antipsychotic medications. Secondly, sensory
processing was predicted by baseline level of uric acid. The
direction of this relationship, seen in Figure 3, suggests that lower
levels of uric acid were associated with greater impairment in
sensory processing tasks.
A commonality among these neurological symptoms is the
degree of complexity of response that is required by the assessment
tasks. In one of the tests that tap the ability to sequence complex
motor acts, for example, the individual is asked to use a steady
rhythmic pattern to touch the table first with his/her fist, then with
the edge of his/her hand, and then with the palm of his/her hand.
The individual is told to repeat this sequence 15 times [13]. The
sensory tasks also demand complex processing and responding by
requiring the integration of auditory, visual, and tactile stimulation
followed by an action that involves either a verbal or other motor
response, such as the placement of a hand or pointing of finger.
Our group has previously documented highly statistically signif-
icant associations between these neurologically-based behaviors
and standard neuropsychological tests of memory and intelligence
in patients with first-episode psychosis who were neuroleptic-naı¨ve
at the time of testing [20]. The present report, which also involved
FENNS patients, provides evidence of linkages between those
same neurologically-based behaviors and metabolites within the
purine pathway, which is closely linked to a series of enzymatic
and non-enzymatic components collectively referred to as the
AODS.
Associations among uric acid, which represents an endpoint of
purine metabolism in humans, and intelligence and achievement
were first reported in the modern research literature over five
decades ago [35–37]. Of interest is the mention by Barrera et al.
[38] of a connection made between uric acid and intelligence that
appeared in the published literature as early as the 1600s. Present
day discussions include the hypothesis that the relative increase in
levels of uric acid in humans, compared to other mammals, may
have conferred an evolutionary advantage [39]. Although
attention to this topic declined during the mid-1980s and
throughout much of the 1990s, recent reports are suggestive of a
growing interest in the contribution of alterations in purine
Figure 2. Pearson correlations between Neurological Evalua-
tion Scale (NES) and ratio of xanthosine to granosine in first-
episode neuroleptic-naı¨ve patients with schizophrenia (FENN-
SZ) at baseline. A, Motor sequencing; B, Repetitive motion. All data
were transformed to natural logarithm (ln). The NES data were available
at baseline from 23 FENN-SZ.
doi:10.1371/journal.pone.0042165.g002
Figure 3. Kendall tau rank correlations between BPRS-thought
disorder and guanosine levels (A), and Pearson correlations
between NES-sensory integration and uric acid levels (B) in
first-episode neuroleptic-naı¨ve patients with schizophrenia
(FENN-SZ) at baseline. The BPRS and NES data were available at
baseline from 23 FENNS-SZ.
doi:10.1371/journal.pone.0042165.g003
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metabolism to illness and disability. Related evidence includes
associations reported between low levels of uric acid and risk for
Parkinson’s Disease (PD) [40], and between low levels of uric acid
and reduced performance on neuropsychological tests of intelli-
gence and attention in patients with this disease [41]. By contrast,
associations have been reported between elevated levels of uric
acid and motor behaviors, including increased uric acid and
hyperactive behaviors in normal preschool children [38], in-
creased uric acid and increased locomotor activity in rats [42], and
an abnormal increase in level of uric acid and psychomotor
excitation in schizophrenia patients during acute illness [43].
Beyond mammals, other evidence implicates a role for purines,
including hypoxanthine and uric acid, in the sensitivity to external
stimuli and motor responses of insects [44]. In combination with
these findings from the research literature, our data are suggestive
of some optimal level of purine byproducts and dynamics in the
integrity of intelligence and manifest behavior.
Limitations
The present study is mainly involved in the purine metabolites
of peripheral blood samples. Whether such an association between
optimal levels of purine byproducts and dynamics in clinical
symptoms is present in the brain awaits further investigation.
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